Cyclo Therapeutics Inc (CYTH)
0.7216
-0.03
(-3.53%)
USD |
NASDAQ |
Nov 01, 16:00
0.7228
0.00 (0.00%)
After-Hours: 20:00
Cyclo Therapeutics Revenue (Quarterly): 0.1231M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.1231M |
| March 31, 2024 | 0.2024M |
| December 31, 2023 | 0.3114M |
| September 30, 2023 | 0.4955M |
| June 30, 2023 | 0.1171M |
| March 31, 2023 | 0.1524M |
| December 31, 2022 | 0.1868M |
| September 30, 2022 | 0.4522M |
| June 30, 2022 | 0.5419M |
| March 31, 2022 | 0.1949M |
| December 31, 2021 | 0.5851M |
| September 30, 2021 | 0.4039M |
| June 30, 2021 | 0.2386M |
| March 31, 2021 | 0.3581M |
| December 31, 2020 | 0.1456M |
| September 30, 2020 | 0.2225M |
| June 30, 2020 | 0.2096M |
| March 31, 2020 | 0.3257M |
| December 31, 2019 | 0.2274M |
| September 30, 2019 | 0.2859M |
| June 30, 2019 | 0.2731M |
| March 31, 2019 | 0.2208M |
| December 31, 2018 | 0.2395M |
| September 30, 2018 | 0.2245M |
| June 30, 2018 | 0.3494M |
| Date | Value |
|---|---|
| March 31, 2018 | 0.1981M |
| December 31, 2017 | 0.1685M |
| September 30, 2017 | 0.2411M |
| June 30, 2017 | 0.5231M |
| March 31, 2017 | 0.3051M |
| December 31, 2016 | 0.5276M |
| September 30, 2016 | 0.2782M |
| June 30, 2016 | 0.3844M |
| March 31, 2016 | 0.3127M |
| December 31, 2015 | 0.1623M |
| September 30, 2015 | 0.2347M |
| June 30, 2015 | 0.3803M |
| March 31, 2015 | 0.1732M |
| December 31, 2014 | 0.446M |
| September 30, 2014 | 0.3875M |
| June 30, 2014 | 0.1736M |
| March 31, 2014 | 0.5603M |
| December 31, 2013 | 0.2342M |
| September 30, 2013 | 0.1673M |
| June 30, 2013 | 0.7083M |
| March 31, 2013 | 0.5835M |
| December 31, 2012 | 0.2975M |
| September 30, 2012 | 0.1574M |
| June 30, 2012 | 0.1482M |
| March 31, 2012 | 0.4419M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.1171M
Minimum
Jun 2023
0.5851M
Maximum
Dec 2021
0.2892M
Average
0.2274M
Median
Dec 2019
Revenue (Quarterly) Benchmarks
| Stryker Corp | 5.494B |
| Biogen Inc | 2.466B |
| Pfizer Inc | 17.70B |
| Pacira BioSciences Inc | 178.02M |
| Moderna Inc | 221.00M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -5.981M |
| Total Expenses (Quarterly) | 5.759M |
| EPS Diluted (Quarterly) | -0.21 |
| Enterprise Value | 22.30M |
| Gross Profit Margin (Quarterly) | 89.13% |
| Profit Margin (Quarterly) | -4.86K% |
| Earnings Yield | -122.0% |
| Normalized Earnings Yield | -122.07 |